An injectable hydrogel containing METTL3 inhibitor can inhibit the methylation of N6-methyladenosine RNA in CRC, resulting in increased expression of CXCL9 and CXCL10, and promoting the migration of CAR-NK cells to eliminate CRC cells (188). Here, CXCL9 is linked to colorectal carcinoma.